Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294805 | 0.88 | PIK3CA (0.39) | PIK3CAMTORKCNH2 | |
| SCHEMBL23294861 | 0.83 | KCNH2 (0.37) | PIK3CAKCNH2 | |
| SCHEMBL23294823 | 0.82 | ATM (0.36) | CNR2TLR9TLR8TLR7ATM | |
| SCHEMBL23294875 | 0.79 | MAOB (0.38) | JAK1ATRPIK3CAKCNH2 | |
| SCHEMBL23294803 | 0.79 | ATM (0.41) | ATMATRPIK3CAMTOR | |
| SCHEMBL23294788 | 0.78 | PIK3CD (0.37) | ATMBRD4PIK3CAKCNH2 | |
| SCHEMBL23294818 | 0.78 | PIK3CA (0.37) | PIK3CAKCNH2 | |
| SCHEMBL23294887 | 0.77 | ATM (0.46) | ATMATRPIK3CAMTORKCNH2 | |
| SCHEMBL23294917 | 0.76 | PIK3CA (0.36) | PIK3CAMTORKCNH2 | |
| SCHEMBL23294811 | 0.75 | MET (0.36) | PIK3CAMTORKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | claimed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | claimed |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | CHEK2, CHEK1, ATM | CNR2 4426/4885TLR9 1982/4885TLR8 2763/4885 |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | CHEK2, CHEK1, ATM | CNR2 4426/4885TLR9 1982/4885TLR8 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.